Tag: FDA GCP expectations

eLearning, VILT & Micro-learning for Investigator and Site Training: A Regulator-Ready Operating Model 2026

Posted on By digi

eLearning, VILT & Micro-learning for Investigator and Site Training: A Regulator-Ready Operating Model Building Effective eLearning, VILT, and Micro-learning for Clinical Sites—Without Compromising Compliance Strategy and Regulatory Anchors for Digital Training at Sites Digital learning is now the default for investigator and site education, yet “online” by itself does not satisfy Good Clinical Practice (GCP)….

Read More “eLearning, VILT & Micro-learning for Investigator and Site Training: A Regulator-Ready Operating Model 2026” »

eLearning, VILT & Micro-learning, Investigator & Site Training

Refresher Training & Retraining Triggers for Investigators and Sites: A Regulator-Ready Playbook 2026

Posted on By digi

Refresher Training & Retraining Triggers for Investigators and Sites: A Regulator-Ready Playbook Building a Risk-Based System for Refresher Training and Retraining at Clinical Sites Why Refresher Training Matters—and How to Anchor It to Regulation Refresher training and targeted retraining protect participants and data precisely when risk is highest: after protocol amendments, safety communications, staff turnover,…

Read More “Refresher Training & Retraining Triggers for Investigators and Sites: A Regulator-Ready Playbook 2026” »

Investigator & Site Training, Refresher Training & Retraining Triggers